Eli Lilly: Among patients with platinum-sensitive ovarian cancer, the first phase clinical data achieved 79% confirmed objective remission rate and 100% disease control rate.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.